EMA Recommends Restrictions on Multiple Sclerosis Medicine
The agency’s Pharmacovigilance Risk Assessment Committee made recommendations on the risk of multiple sclerosis treatments, injectable methylprednisolone medicines, and the use of gadolinium contrast agents.
The European Medicines Agency (EMA) announced on July 7, 2017 that its Pharmacovigilance Risk Assessment Committee (PRAC) had concluded two referrals and issued provisional measures for the treatment of multiple sclerosis. The committee is provisionally restricting the use of Zinbryta (daclizumab) “to patients with highly active relapsing disease that failed to respond to certain other treatments, and to patients with rapidly evolving relapsing disease who cannot be treated with other medicines.” EMA stated in a press release that the drug should not be given to patients with liver injury and doctors should closely monitor liver function in patients taking the drug.
PRAC recommended that injectable methylprednisolone medicines containing lactose must not be used by patients with an allergy to the proteins in cow’s milk. The committee also recommended that cow’s milk proteins be removed from the preparation of injectable methylprednisolone. Injectable methylprednisolone is used to treat the symptoms of severe allergic reaction.
At the meeting, PRAC confirmed its restrictions on the use of linear gadolinium agents.
The committee previously determined that there is evidence of gadolinium deposition in brain tissues following use of gadolinium contrast agents.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
